Risks for biliary tract cancer

Last medical review:

Some things can affect your risk, or chance, of developing cancer. Certain behaviours, substances or conditions can increase or decrease the risk. Most cancers are the result of many risks. But sometimes cancer develops in people who don't have any risks.

Having gallstones is the main risk for biliary tract cancer, which includes gallbladder cancer and bile duct cancer.

The risk of developing biliary tract cancer increases with age. More women than men develop gallbladder cancer, while more men than women develop bile duct cancer.

Gallbladder cancer rates are higher in certain countries and ethnic groups. In North America, the number of people who get gallbladder cancer is low, but the rate of gallbladder cancer for people with Indigenous and Latin American ancestry is higher than average.

Some of the things that increase the risk for biliary tract cancer may also cause precancerous conditions. Precancerous conditions of the biliary tract include gallbladder polyps and biliary intraepithelial neoplasia. They are not cancer, but they can sometimes become biliary tract cancer if they are not treated.

The following can increase your risk for biliary tract cancer. Many of these risks can't be changed. But in some cases, there are things you can do to lower your risk.

Gallstones

Chronic inflammation of the biliary tract

Choledochal cysts

Anomalous junction of the pancreaticobiliary duct

Excess weight

Certain infections

Inflammatory bowel disease

Contact with Thorotrast

Contact with 1,2-dichloropropane

Gallstones

Gallstones are stone-like masses that form when the substances that make up bile harden. Having gallstones is called cholelithiasis. It's a common condition, but it develops more often in women.

Although having a history of gallstones is the most common risk for biliary tract cancer, only a very small number of people with gallstones will develop gallbladder cancer.

Chronic inflammation of the biliary tract

Conditions that cause inflammation of the biliary tract increase the risk of developing gallbladder or bile duct cancer.

Cholecystitis is inflammation of the gallbladder. It's most commonly caused by gallstones blocking the bile ducts. Over time, inflammation damages the gallbladder, causing scarring and thickening of the gallbladder walls.

Porcelain gallbladder is a rare condition. It happens when calcium builds up on the walls of the gallbladder, causing them to harden (calcify). It usually occurs when the gallbladder wall is heavily scarred due to chronic cholangitis (bile duct inflammation).

Primary sclerosing cholangitis is inflammation of the bile ducts. Over time, inflammation damages the bile duct walls, causing scarring and narrowing of the bile ducts.

Choledochal cysts

Choledochal cysts are a rare congenital condition of the biliary tract that cause abnormally wide (dilated) bile ducts. They can cause inflammation and an abnormal flow of bile in the bile ducts and gallbladder.

There are 5 types of choledochal cysts. They are classified according to the location and amount of dilation. Type 5 (also called Caroli disease) is the most severe. When it's combined with a buildup of liver scarring (fibrosis), it's called Caroli syndrome.

Anomalous junction of the pancreaticobiliary duct

The pancreaticobiliary duct junction is the point where the pancreatic duct and the common bile duct join. Anomalous junction of the pancreaticobiliary duct (AJPD) is a rare congenital abnormality that causes this junction to be outside the wall of the duodenum.

AJPD causes pancreatic digestive juices to flow back into the bile ducts instead of into the small intestine. This can cause inflammation of the biliary tract.

Excess weight

Overweight or obesity increases the risk for biliary tract cancer.

Learn more about how to have a healthy body weight.

Certain infections

Infections with the following parasites or bacteria increase the risk of developing biliary tract cancer.

Liver flukes are a group of parasites, including Opisthorchis viverrini (O. viverrini) and Clonorchis sinensis (C. sinensis). They can cause inflammation of the liver and biliary tract. Eating raw or undercooked freshwater fish or shrimp from areas where liver flukes are found can allow the infection to enter the body. Sometimes you can have the parasites in your body but not have any symptoms for many years. Infection with liver flukes increases the risk for bile duct cancer.

Salmonella typhi (S. typhi) is a type of bacteria that causes typhoid fever. Sometimes you can have the bacteria in your body but not have any symptoms. Typhoid fever can be spread from person to person through contact with stool (poop) or urine (pee). Infection with S. typhi, even if it doesn't cause symptoms, increases the risk for gallbladder cancer.

Inflammatory bowel disease

Inflammatory bowel disease (IBD) is another name for ulcerative colitis and Crohn's disease. IBD is a type of autoimmune disease that causes inflammation of the gastrointestinal tract. Studies show that people with IBD have a higher risk for cancer of the biliary tract. People with both IBD and primary sclerosing cholangitis have an even higher risk.

Contact with Thorotrast

Thorium dioxide (Thorotrast) is a contrast medium that was used for imaging tests in the past. Studies show that people who were injected with Thorotrast have a higher risk for gallbladder cancer.

Contact with 1,2-dichloropropane

Coming into contact with 1,2-dichloropropane at work increases the risk for biliary tract cancer.

1,2-dichloropropane is a chemical used in the printing, rubber-making and wax-making industries, as well as in the production of other chemicals. Coming into contact with 1,2-dichloropropane increases the risk for bile duct cancer.

Find out more about how to be safe at work.

Possible risks

The following have been linked with biliary cancer, but more research is needed to know for sure that they are risks:

  • family history of gallbladder or bile duct cancer
  • type 2 diabetes
  • hepatitis B virus (HBV) and hepatitis C virus (HCV) infection
  • Helicobacter pylori (H. pylori) infection (a bacteria that infects the stomach)
  • number of pregnancies a woman has had (parity)
  • cirrhosis of the liver or biliary tract
  • drinking alcohol
  • smoking tobacco

Understanding your cancer risk

To make the decisions that are right for you, ask your doctor questions about risks. Learn how cancer can be prevented and what you can do to reduce your risk.

Expert review and references

  • Canadian Cancer Society | Société canadienne du cancer
  • American Institute for Cancer Research, World Cancer Research Fund. Continuous Update Project Report: Body Fatness and Weight Gain and the Risk of Cancer. 2018. https://www.aicr.org/.
  • American Institute for Cancer Research / World Cancer Research Fund. Continuous Update Project Report: Diet, Nutrition, Physical Activity and Stomach Cancer. 2018. https://www.wcrf.org/.
  • Binda C, Gibiino G, Coluccio C, Sbrancia M, Dajti E, Sinagra E, et al.. Biliary diseases from the microbiome perspective: How microorganisms could change the approach to benign and malignant diseases. Microorganisms. 2022: 10(2):312.
  • Chen J, Ke K, Liu Z, Yang L, Wang L, Zhou J, et al.. Body mass index and cancer risk: an umbrella review of meta-analyses of observational studies. Nutrition and Cancer. 2023: 75(4):1051–1064.
  • Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan A. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Journal of Hepatology. 2020: 72(1):95–103.
  • Ellington TD, Momin B, Wilson RJ, Henley SJ, Wu M, Ryerson AB. Incidence and mortality of cancers of the biliary tract, gallbladder, and liver by sex, age, race/ethnicity, and stage at diagnosis: United States, 2013-2017. Cancer Epidemiology, Biomarkers, and Prevention. 2021: 30(9):1607–1614.
  • Gros B, Gómez Perez A, Pleguezelo M, Serrano Ruiz FJ, de la Mata M, Rodríguez-Perálvarez M. Helicobacter species and hepato-biliary malignancies: A systematic review and meta-analysis. Cancers. 2023: 15(3):595.
  • Hemminki K, Försti A, Hemminki O, Liska V, Hemminki A. Long-term survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway, and Sweden with etiological implications related to thorotrast. International Journal of Cancer. 2022: 151(2):200–208.
  • International Agency for Research on Cancer (IARC). Volume 100B: Biological agents: A Review of Human Carcinogens. 2012. http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B.pdf.
  • International Agency for Research on Cancer (IARC). Volume 100D: Radiation: A Review of Human Carcinogens. 2011. http://monographs.iarc.fr/ENG/Monographs/vol100D/mono100D.pdf.
  • International Agency for Research on Cancer (IARC). Volume 100E: Personal Habits and Indoor Combustions. 2012. http://monographs.iarc.fr/ENG/Monographs/vol100E/mono100E.pdf.
  • International Agency for Research on Cancer (IARC). Volume 110: Some Chemicals Used as Solvents and in Polymer Manufacture: A Review of Human Carcinogens. 2016. https://publications.iarc.fr/547.
  • Jackson SS, Van Dyke AL, Zhu B, Pfeiffer RM, Petrick JL, Adami HO, et al.. Anthropomorphic risk factors for cancer of the biliary tract in the Biliary Tract Cancers Pooling Project. Cancer Research. 2019: 79(15):3973–3983.
  • Jackson SS, Adami HO, Andreotti G, Beane-Freenman LE, de Gonzálezx AB, Buring JE, et al.. Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project. Journal of Hepatology. 2020: 73(4):863–872.
  • Kamisawa T, Kaneko K, Hoi T, Ando H. Pancreaticobiliary maljunction and congenital biliary dilation. The Lancet. 2017: 2(8):610–618.
  • Koshiol J, Ferreccio C, Devesa SS, Roa JC, Fraumeni JF. Biliary tract cancer. Thun MJ, Linet MS, Cerhan JR, Haiman CA Schottenfeld D, eds.. Schottenfeld and Fraumeni Cancer Epidemiology and Prevention. 4th ed. New York, NY: Oxford University Press; 2018: Kindle version, [chapter 34] https://read.amazon.ca/?asin=B0777JYQQC&language=en-CA.
  • Liang Y, Yang Z, Zhong R. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology. Baltimore, MD: 2012: 56(4):1409–1417.
  • Lugo A, Peveri G, Gallus S. Should we consider gallbladder cancer a new smoking-related cancer? A comprehensive meta-analysis focused on dose-response relationships. International Journal of Cancer. 2020: 146(12):3304–3311.
  • Makiuchi T, Sobue T, Kitamura T, Sawada N, Iwasaki M, Yamaji T, et al.. Smoking, alcohol consumption, and risks for biliary tract cancer and intrahepatic bile duct cancer. Journal of Epidemiology. 2019: 29(5):180–186.
  • Marie C, Petri WA. Fluke infections of the liver. Merck Manual Consumer Version. Kenilworth, NJ: Merck & Co, Inc; 2023. https://www.merckmanuals.com/en-ca/home.
  • McGee EE, Jackson SS, Petrick JL, Van Dyke AL, Adamiu HO, Albanes D, et al.. Smoking, alcohol, and biliary tract cancer risk: a pooling project of 26 prospective studies. Journal of the National Cancer Institute. 2019: 111(12):1263–1278.
  • Murthy SK, Kuenzig ME, Windsor JW, Matthews P, Tandon P, Benchimol EI, et al.. The 2023 impact of inflammatory bowel disease in Canada: cancer and IBD. Journal of the Canadian Association of Gastroenterology. 2023: 6(Supp 2):S83–S96.
  • National Center for Advancing Translational Sciences, Genetic and Rare Diseases Information Center. Caroli Disease. National Institutes of Health; 2023. https://rarediseases.info.nih.gov/.
  • National Toxicology Program. Report on Carcinogens Monograph on Helicobacter pylori (Chronic Infection). Department of Health and Human Services; 2018. https://ntp.niehs.nih.gov/ntp/roc/monographs/hpylori_final20181026_508.pdf.
  • National Toxicology Program. Report on Carcinogens. 15 ed. Research Triangle Park, NC: US Department of Health and Human Services, Public Health Service; 2021. https://ntp.niehs.nih.gov/whatwestudy/assessments/cancer/roc/index.html.
  • Oh EH, Kim YJ, Kim M, Park SH, Kim TO, Park SH. Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study. Intestinal Research. 2023: 21(2):252–265.
  • Park JH, Hong JY, Han K, Park YS, Park JO. Light to moderate alcohol consumption increases the risk of biliary tract cancer in prediabetes and diabetes but not in normoglycemic status: a nationwide cohort study. Journal of Clinical Oncology. 2022: 40(31):3623–3632.
  • Saiman Y. Cholecystitis. Merck Manual Consumer Version. Kenilworth, NJ: Merck & Co, Inc; 2023. https://www.merckmanuals.com/en-ca/home.
  • Saiman Y. Primary sclerosing cholangitis. Merck Manual Consumer Version. Kenilworth, NJ: Merck & Co, Inc; 2023. https://www.merckmanuals.com/en-ca/home.
  • Seeherunwong A, Chaiear N, Kluntikeo N, Epanyaskul C. Cholangiocarcinoma attributed to occupation: a systematic review. Asian Pacific Journal of Cancer Prevention. 2022: 23(6):1837–1845.
  • Statistics Canada. Table: 13-10-0111-01: Number and rates of new cases of primary cancer, by cancer type, age group and sex. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310011101. June 19, 2024.
  • Umar J, Kudaravali P, John S. Caroli disease. StatPearls [Internet]. 2023.
  • Yu J, Refsum E, Helsingen LM, Folseraas T, Ploner A, Wieszczy P, et al.. Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: a population-based cohort study. United European Gastroenterology Journal. 2022: 10(2):212–224.
  • Zulfiqar M, Chatterjee D, Yoneda N, Hoegger MJ, Ronot M, Hecht EM, et al.. Imaging features of premalignant biliary lesions and predisposing conditions with pathologic correlations. Radiographics. 2022: 42(5):1320–1337.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society